A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…
Read More
It is safe for malignant mesothelioma patients to combine Tremelimumab and Imfinzi (durvalumab), according to a study to be presented at the 2017 American Society of Clinical…
Read More
A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the…
Read More
Researchers found that a protein with anti-cancer activity, which is isolated from the bullfrog, may be a good treatment option for mesothelioma, including in standard-of-care…
Read More
Even though 40 years have passed since their exposure to asbestos, workers’ risk of developing mesothelioma continues to rise, new research shows. Individuals exposed to asbestos four decades ago…
Read More
French researchers have used mathematical modeling to select the best treatment schedule and dosing of Navelbine (vinorelbine) chemotherapy for mesothelioma and non-small cell lung cancer (NSCLC)…
Read More
The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of…
Read More
Immunotherapy may be the way to tackle malignant pleural mesothelioma (MPM) after relapse, a new Phase 2 trial suggests. Using Opdivo (nivolumab) alone or in combination with…
Read More
Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell…
Read More
Adding nintedanib to chemotherapy led to a 64 percent increase in the time it took for mesothelioma patients’ disease to progress, compared with chemo alone,…
Read More
